-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $405

Benzinga·02/27/2026 15:07:18
Listen to the news
Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $394 to $405.